Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Enterprise Value (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Enterprise Value for 8 consecutive years, with -$540.7 million as the latest value for Q1 2026.

  • Quarterly Enterprise Value rose 1.63% to -$540.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$540.7 million through Feb 2026, up 1.63% year-over-year, with the annual reading at -$592.9 million for FY2025, 2.73% up from the prior year.
  • Enterprise Value for Q1 2026 was -$540.7 million at Nurix Therapeutics, up from -$592.9 million in the prior quarter.
  • The five-year high for Enterprise Value was -$244.0 million in Q1 2024, with the low at -$609.6 million in Q4 2024.
  • Average Enterprise Value over 5 years is -$391.8 million, with a median of -$344.5 million recorded in 2022.
  • The sharpest move saw Enterprise Value increased 24.86% in 2023, then crashed 125.29% in 2025.
  • Over 5 years, Enterprise Value stood at -$309.1 million in 2022, then grew by 6.87% to -$287.9 million in 2023, then crashed by 111.73% to -$609.6 million in 2024, then increased by 2.73% to -$592.9 million in 2025, then rose by 8.81% to -$540.7 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$540.7 million, -$592.9 million, and -$428.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.